Catalyst Dossier · compiled by CeliA 🧫

ANAVEX LIFE SCIENCES CORP. (AVXL)

Biological Products, (No Diagnostic Substances) · market cap $253M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ANAVEX2-73	Phase 3	Alzheimer's Disease
Mid dose ANAVEX2-73	Phase 3	Alzheimer Disease
ANAVEX2-73 Oral	Phase 2	Alzheimer's Disease
ANAVEX2-73 oral liquid	Phase 3	Rett Syndrome
ANAVEX3-71 oral capsules	Phase 2	Schizophrenia
High dose ANAVEX2-73	Phase 3	Parkinsons Disease With Dementia

Price & technical context

3-month

-16.0%

6-month

-29.3%

12-month

-72.0%

52-wk range

$2.46–$13.41

vs 50-day MA

-10.8%

vs 200-day MA

-45.5%

Realized vol

94.7%

Max drawdown

-81.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AVXL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.